Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
321841 | European Neuropsychopharmacology | 2012 | 4 Pages |
Abstract
The preferential dopamine D3-agonist pramipexole (4.25±0.38 mg/day) or placebo were added for up to 12 weeks to ongoing antipsychotic treatment for 24 adult patients with DSM-IV schizophrenia or schizoaffective disorder. Pramipexole was generally well-tolerated (82% trial-completion), and yielded greater decreases in PANSS-total scores (drug/placebo = 2.1; p = 0.04), with similar decreases in PANSS positive and negative scores and 6.7-fold greater reduction of serum prolactin concentrations compared to placebo. There were no differences in ratings of mood, cognition or extrapyramidal symptoms, all of which were low at intake.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
James P. Kelleher, Franca Centorrino, Nancy A. Huxley, John A. Bates, Jennifer Kidwell Drake, Samy Egli, Ross J. Baldessarini,